Titan Pharmaceuticals Inc financial data

Symbol
TTNP on Nasdaq, TTNPW on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
400 Oyster Point Blvd, Suite 505, San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 684 % +461%
Quick Ratio 11.2 % +24%
Debt-to-equity 17 % -93.8%
Return On Equity -87.9 % +90.7%
Return On Assets -75.1 % +70.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 914K shares -93.9%
Common Stock, Shares, Outstanding 914K shares -93.9%
Entity Public Float 7.3M USD -71.5%
Weighted Average Number of Shares Outstanding, Basic 914K shares +21.7%
Weighted Average Number of Shares Outstanding, Diluted 914K shares +21.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.91M USD -59.8%
General and Administrative Expense 6.22M USD +12%
Costs and Expenses 2.47M USD -9.75%
Operating Income (Loss) -7.13M USD +16.5%
Nonoperating Income (Expense) 1.67M USD +2154%
Net Income (Loss) Attributable to Parent -5.46M USD +35.5%
Earnings Per Share, Basic -6.6 USD/shares -8.53%
Earnings Per Share, Diluted -6.6 USD/shares +65.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.09M USD +3797%
Accounts Receivable, after Allowance for Credit Loss, Current 38K USD +322%
Inventory, Net 0 USD -100%
Assets, Current 4.35M USD +773%
Property, Plant and Equipment, Net 3K USD -98.3%
Operating Lease, Right-of-Use Asset 32K USD -79.2%
Other Assets, Noncurrent 48K USD 0%
Assets 4.35M USD +436%
Accounts Payable, Current 356K USD -40.4%
Liabilities, Current 356K USD -80.7%
Operating Lease, Liability, Noncurrent 33K USD -79.1%
Liabilities 356K USD -80.7%
Retained Earnings (Accumulated Deficit) -395M USD -1.4%
Stockholders' Equity Attributable to Parent 3.99M USD
Liabilities and Equity 4.35M USD +436%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -613K USD +67.7%
Net Cash Provided by (Used in) Financing Activities 4.98M USD -43.7%
Common Stock, Shares Authorized 225M shares 0%
Common Stock, Shares, Issued 914K shares -93.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.09M USD +3254%
Interest Paid, Excluding Capitalized Interest, Operating Activities 13K USD
Deferred Tax Assets, Valuation Allowance 65M USD -7.55%
Deferred Tax Assets, Gross 65M USD -7.58%
Operating Lease, Liability 33K USD -79.1%
Lessee, Operating Lease, Liability, to be Paid 33K USD -79.9%
Property, Plant and Equipment, Gross 711K USD -60.9%
Operating Lease, Liability, Current 33K USD -73.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 66K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 33K USD -66.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD -88.9%
Deferred Tax Assets, Operating Loss Carryforwards 53.2M USD -8.07%
Preferred Stock, Shares Issued 950K shares
Preferred Stock, Shares Authorized 5M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 399M USD +2.7%
Preferred Stock, Shares Outstanding 950K shares
Depreciation, Depletion and Amortization 2K USD -95.3%
Share-based Payment Arrangement, Expense 1.01M USD +6.97%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares